These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36822542)

  • 1. Iron chelation alleviates multiple pathophysiological pathways in a rat model of cardiac pressure overload.
    Lupu M; Coada CA; Tudor DV; Baldea I; Florea A; Toma VA; Lupsor A; Moldovan R; Decea N; Filip GA
    Free Radic Biol Med; 2023 May; 200():1-10. PubMed ID: 36822542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral deferiprone for iron chelation in people with thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Chowdhury O; Gooding S; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004839. PubMed ID: 23966105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
    Emara AM; El Kelany RS; Moustafa KA
    Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iron chelation effects on lipid peroxidation, inflammation and ventricular performance in a rat model of isoproterenol induced acute myocardial stress.
    Lupu M; Tudor DV; Toma VA; Florea A; Lupsor A; Moldovan R; Stancu B; Decea N; Filip AG
    J Physiol Pharmacol; 2022 Jun; 73(3):. PubMed ID: 36302532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications.
    Chuang TY; Li JP; Weng TF; Wu KH; Chao YH
    Ann Hematol; 2020 Oct; 99(10):2289-2294. PubMed ID: 32737633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusional iron overload and chelation therapy with deferoxamine and deferiprone (L1).
    Kontoghiorghes GJ; Pattichi K; Hadjigavriel M; Kolnagou A
    Transfus Sci; 2000 Dec; 23(3):211-23. PubMed ID: 11099897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice.
    Kumfu S; Chattipakorn SC; Fucharoen S; Chattipakorn N
    Exp Physiol; 2016 Apr; 101(4):521-39. PubMed ID: 26824522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron and oxidative stress in cardiomyopathy in thalassemia.
    Berdoukas V; Coates TD; Cabantchik ZI
    Free Radic Biol Med; 2015 Nov; 88(Pt A):3-9. PubMed ID: 26216855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine.
    Wongjaikam S; Kumfu S; Khamseekaew J; Chattipakorn SC; Chattipakorn N
    Sci Rep; 2017 Mar; 7():44460. PubMed ID: 28287621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association.
    Pennell DJ; Udelson JE; Arai AE; Bozkurt B; Cohen AR; Galanello R; Hoffman TM; Kiernan MS; Lerakis S; Piga A; Porter JB; Walker JM; Wood J;
    Circulation; 2013 Jul; 128(3):281-308. PubMed ID: 23775258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
    Kolnagou A; Kontoghiorghes GJ
    Front Biosci (Landmark Ed); 2018 Jan; 23(6):1082-1098. PubMed ID: 28930590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine.
    Kontoghiorghes GJ; Neocleous K; Kolnagou A
    Drug Saf; 2003; 26(8):553-84. PubMed ID: 12825969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Roberts DJ; Rees D; Howard J; Hyde C; Alderson P; Brunskill S
    Cochrane Database Syst Rev; 2005 Oct; (4):CD004450. PubMed ID: 16235363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation response.
    Aydinok Y; Evans P; Manz CY; Porter JB
    Haematologica; 2012 Jun; 97(6):835-41. PubMed ID: 22180427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
    Wood JC; Otto-Duessel M; Gonzalez I; Aguilar MI; Shimada H; Nick H; Nelson M; Moats R
    Transl Res; 2006 Nov; 148(5):272-80. PubMed ID: 17145573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice.
    Khamseekaew J; Kumfu S; Wongjaikam S; Kerdphoo S; Jaiwongkam T; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    Eur J Pharmacol; 2017 Mar; 799():118-127. PubMed ID: 28192097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.